Method for preparing human pluripotent stem cell-derived testicular interstitial-like cells and human pluripotent stem cell-derived testicular interstitial-like cell population

By forcibly expressing the NR5A1 gene in human pluripotent stem cells and processing specific cytokines, it was successfully induced into testicular interstitial cells, solving the problems of unstable testosterone secretion and low differentiation efficiency in the prior art, and achieving efficient testosterone secretion and long-term secretion ability.

CN118984871APending Publication Date: 2024-11-19KOBE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032988.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-15
Filing Date
2023-02-08
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing methods are difficult to stabilize and sustainably secrete testosterone-induced interstitial cells of human pluripotent stem cells, and have low differentiation induction efficiency.

Method used

By forced expression of the NR5A1 gene in human pluripotent stem cells and suspended culture in the presence of WNT classical pathway activator, BMP4 and VEGF, followed by adherent culture, and cAMP and forskolin removal, as appropriate, to induce Differentiate into testicular interstitial cells.

Benefits of technology

Testicular interstitial-like cells derived from human pluripotent stem cells that can secrete testosterone for a long time have achieved differentiation induction efficiency of 80% or higher, and cells can continuously produce testosterone for at least 60 days.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984871A_ABST
    Figure CN118984871A_ABST
Patent Text Reader

Abstract

The invention provides a method for preparing testicular interstitial-like cells (testicular interstitial-like cells) derived from human pluripotent stem cells capable of stably and continuously secreting testosterone, and testicular interstitial-like cells derived from human pluripotent hepatocytes. The invention also provides a human pluripotent stem cell-derived testicular interstitial cell which can maintain the testicular interstitial cell to secrete enough testosterone for a long time and improve the efficiency of differentiation induction. The method comprises the following steps: culturing human pluripotent stem cells under a culture condition in which one or more of a WNT classical pathway activator, a bone morphogenetic protein 4 (BMP4) and a vascular endothelial growth factor (VEGF) are added, and forcibly expressing NR5A1 by controlling addition and removal time of cyclic adenosine monophosphate (cAMP), suspension culture, adherent culture and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for preparing human pluripotent stem cell-derived Leydig-like cells and a human pluripotent stem cell-derived Leydig-like cell population.

[0002] This application claims the benefit of Japanese Patent Application No. 2022-021533, which is hereby incorporated by reference. Background Art

[0003] In recent years, attention has been focused on the age-related male hypogonadism syndrome (late-onset hypogonadism (LOH) syndrome), which is caused by an age-related decline in male hormones and triggers various symptoms. To address this problem, hormone replacement therapy with testosterone has been performed. However, hormone replacement therapy produces hormone values ​​that differ from the physiological secretion pattern and has a short duration of action, thus requiring repeated administration, placing a heavy burden on patients. There has been a need to develop a new treatment method that does not require repeated administration, improves aspects such as time spent in medical consultations, injection-related work and pain, and improves the quality of life (QOL).

[0004] The hypothalamus produces gonadotropin-releasing hormone (GnRH). In response to the production of GnRH, the anterior pituitary produces luteinizing hormone (LH) and follicle stimulating hormone (FSH). It is estimated that the Leydig cells in the testicles produce 5 mg to 10 mg of testosterone per day in response to LH. Testosterone is synthesized from cholesterol via several intermediate compounds, such as dehydroepiandrosterone (DHEA) and androstenedione.

[0005] There are attempts to develop methods for inducing differentiation into various cells using pluripotent stem cells that have self-replication and multi-lineage potential. Techniques using embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) among pluripotent stem cells have attracted attention. Various attempts have been made to induce differentiation into steroid hormone-producing cells of the testis and adrenal gland by stably introducing steroidogenic factor-1 (SF-1) as a transcription factor into various mesenchymal stem cells and adding cyclic adenosine monophosphate (cAMP) to the culture medium. SF-1 is a member of the nuclear receptor family of intracellular transcription factors and is encoded by the nuclear receptor subfamily 5 group A member 1 (NR5A1) gene.

[0006] A method has been reported in which SF-1 is introduced into two types of human ES cells (H9 strain and KhES1 strain) and one type of human iPS cell line (201B7 strain) to induce differentiation into steroid hormone-producing cells. In this method, each human ES cell line and human iPS cell line are induced to differentiate into mesodermal cells by using 6-bromoindirubin-3′-oxime (BIO) and a glycogen synthase kinase 3 (GSK-3) inhibitor, and the mesodermal cells are sorted by flow cytometry. SF-1 is then introduced into mesodermal cells containing a plasmid of pCMFlag-hsNR5A1 to express SF-1, thereby achieving expression. The resulting cells are further cultured in a medium containing 8-bromo-cAMP (8-Br-cAMP) and induced to differentiate into steroid hormone-producing cells. However, the report mentions the production of progesterone and cortisol, but does not describe the production of testosterone, nor does it disclose the expression of markers (INSL3, 17βHSD3, LHCGR, etc.) that are selective markers for testicular Leydig cells (Non-Patent Document 1).

[0007] In another disclosed method, mouse pluripotent stem cells (ES cells) are induced to differentiate into mesenchymal stem cells, which are then expressed under the conditions of SF-1 to differentiate into steroid hormone-producing cells (Patent Document 1). However, this invention does not report the production of hormones such as testosterone and cortisol, nor does it show the expression of markers that are markers of testicular interstitial cells.

[0008] A report describes the use of a lentiviral vector to introduce mouse SF-1 into mouse ES cells (OriCellStrain C57BL / 6mESC) to produce SF-1 + ESC strain (ESC-SF-1) was then further cultured in a medium containing 8-Br-cAMP and forskolin, and induced to differentiate into Leydig progenitor cells (PLC). The description shows that treatment of ESC-SF-1 with 8-Br-cAMP and forskolin induces PLC differentiation more effectively than treatment with 8-Br-cAMP alone. In the report, the PLCs thus obtained were transplanted into rats as Leydig-like cells, and markers that are markers of Leydig cells were then measured from serum samples, etc. (Non-Patent Document 2).

[0009] One disclosure provides a method in which NR5A1 is expressed in human pluripotent stem cells to produce human pluripotent stem cell-derived Leydig-like cells expressing INSL3 and also expressing at least one marker selected from 17βHSD3 and LHCGR (Patent Document 2). In addition, another disclosure shows a method for producing human pluripotent stem cell-derived Leydig-like cells expressing HSD17B3, INSL3, LHCGR, etc. (Non-Patent Document 3). However, it is necessary to prepare human pluripotent stem cell-derived Leydig-like cells that can continuously secrete testosterone more stably.

[0010] Citation List

[0011] Non-patent literature

[0012] [NPL 1]Endocrinology,153(9):4336-4345(2012)

[0013] [NPL 2]STEM CELLS AND DEVELOPMENT,24(4):459-470(2015)

[0014] [NPL 3]Endocrinology,2021,Vol.162,No.12,1-11,https: / / doi.org / 10.1210 / endocr / bqab202

[0015] Patent Literature

[0016] [PTL 1] JP 2011-15630A

[0017] [PTL 2]WO 2018 / 088240A1(JP 6979702 B2) Summary of the invention

[0018] Technical issues

[0019] The purpose of the present invention is to provide a method for preparing human pluripotent stem cell-derived Leydig-like cells capable of stably and continuously secreting testosterone, and a human pluripotent stem cell-derived Leydig-like cell. Another purpose of the present invention is to provide a human pluripotent stem cell-derived Leydig-like cell capable of maintaining Leydig-like cells that secrete sufficient amounts of testosterone for a long time and improving the efficiency of differentiation induction.

[0020] Problem Solution

[0021] To achieve the above-mentioned object, the inventors of the present invention have conducted earnest research and thus found that Leydig-like cells capable of stably and persistently secreting testosterone can be provided by a method for preparing Leydig-like cells derived from human pluripotent stem cells, the method comprising the step of culturing human pluripotent stem cells under culture conditions in which a cytokine mixture is added and NR5A1 is forcibly expressed, wherein various designs are made for the time for adding or removing cAMP, suspension culture, adherent culture, etc. Thus, the inventors have accomplished the present invention.

[0022] That is, the present invention includes the following contents.

[0023] 1. A method for preparing human pluripotent stem cell-derived Leydig-like cells, comprising the step of forcibly expressing NR5A1 in human pluripotent stem cells, wherein the method comprises the step of adding one or more selected from WNT classical pathway activators, bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF) to the culture system of human pluripotent stem cells.

[0024] 2. A method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 1 above, wherein the method comprises the step of forcibly expressing NR5A1 in human pluripotent stem cells in the presence of one or more selected from WNT classical pathway activators, BMP4 and VEGF, followed by suspension culture for 2 to 10 days, and then adherent culture.

[0025] 3. A method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 1 above, wherein the method comprises the step of forcibly expressing NR5A1 in human pluripotent stem cells in the presence of one or more selected from WNT classical pathway activators, BMP4 and VEGF, followed by suspension culture until the human pluripotent stem cells begin to form blastoderm, followed by adherent culture.

[0026] 4. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 2 or 3 above, wherein the adherent culture step comprises the step of removing the existing WNT classical pathway activator, BMP4 and VEGF, and then adding cAMP.

[0027] 5. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 4 above, wherein the method comprises the step of removing cAMP from the culture system during the period from day 2 to day 40 after the start of treatment with cAMP.

[0028] 6. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 4 above, wherein the adherent culture step comprises the step of removing the existing WNT canonical pathway activator, BMP4 and VEGF, and then treating with forskolin.

[0029] 7. A method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 1 above, wherein the step of forcibly expressing NR5A1 in human pluripotent stem cells in the presence of one or more selected from WNT classical pathway activators, BMP4 and VEGF is carried out on a culture device capable of forming an embryoid body of 50 to 20,000 cells.

[0030] 8. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 1 above, wherein the step of forcibly expressing NR5A1 in the human pluripotent stem cells comprises using a Tet-Off (trademark name) system in a tetracycline-dependent gene expression system, wherein the Tet-Off system forces expression of NR5A1 in the absence of tetracycline or doxycycline.

[0031] 9. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 2 or 3 above, wherein the method comprises a step of further performing suspension culture after performing suspension culture and adherent culture.

[0032] 10. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to item 1 above, wherein the differentiation induction efficiency from the human pluripotent stem cells to the human pluripotent stem cell-derived Leydig-like cells is 80% or more.

[0033] 11. A human pluripotent stem cell-derived Leydig-like cell prepared by the method of item 1 above.

[0034] 12. The human pluripotent stem cell-derived Leydig-like cells according to item 11 above, wherein the human pluripotent stem cell-derived Leydig-like cells are Leydig-like cells that continuously produce testosterone for at least 60 days.

[0035] 13. A human pluripotent stem cell-derived Leydig-like cell, which is obtained after the human pluripotent stem cell-derived Leydig-like cell according to item 11 above is passaged at least once.

[0036] 14. A human pluripotent stem cell-derived Leydig-like cell population, comprising the human pluripotent stem cell-derived Leydig-like cells described in item 11 above.

[0037] 15. The human pluripotent stem cell-derived Leydig-like cell population according to item 14 above, wherein the cell population comprises 80% or more of Leydig-like cells capable of producing testosterone.

[0038] 16. The human pluripotent stem cell-derived Leydig-like cell population according to item 14 or 15 above, wherein the cell population is subjected to immunoisolation.

[0039] 17. A pharmaceutical composition for treating a disease associated with testosterone reduction, comprising the human pluripotent stem cell-derived Leydig-like cell population of item 14 or 15 above as an active ingredient.

[0040] 18. A composition for cell transplantation, comprising a biocompatible membrane, to which the human pluripotent stem cell-derived Leydig-like cell population according to item 14 or 15 above adheres.

[0041] 19. A device for transplantation of endocrine cells derived from pluripotent stem cells, comprising a biocompatible membrane for implanting endocrine cells derived from pluripotent stem cells into a living body.

[0042] 20. The device for transplantation of pluripotent stem cell-derived endocrine cells according to item 19 above, wherein the pluripotent stem cell-derived endocrine cells are human pluripotent stem cell-derived endocrine cells capable of producing testosterone.

[0043] 21. The device for transplantation of endocrine cells derived from pluripotent stem cells according to item 20 above, wherein the endocrine cells derived from human pluripotent stem cells capable of producing testosterone are the interstitial-like cells derived from human pluripotent stem cells according to item 11 above.

[0044] A. A method for transplanting a population of Leydig-like cells derived from human pluripotent stem cells into a living body.

[0045] B. The transplantation method according to item A above, wherein the Leydig-like cell population derived from human pluripotent stem cells is transplanted into a living body together with a biocompatible membrane to which the cell population adheres.

[0046] C. The transplantation method according to item A above, wherein a composition for cell transplantation comprising a biocompatible membrane is transplanted into a living body, and the mesenchymal-like cell population derived from human pluripotent stem cells adheres to the biocompatible membrane.

[0047] D. A transplantation method according to any one of items A to C above, wherein the human pluripotent stem cell-derived Leydig-like cell population is a cell population of human pluripotent stem cell-derived Leydig-like cells produced by a method comprising the steps of adding one or more selected from WNT classical pathway activators, BMP4, and VEGF to a culture system of human pluripotent stem cells.

[0048] E. A method for treating a disease associated with testosterone reduction, the method comprising administering a pharmaceutical composition containing a population of Leydig-like cells derived from human pluripotent stem cells as an active ingredient.

[0049] F. A method for treating a disease associated with decreased testosterone, or a method for treating a symptom requiring testosterone replacement, the method comprising transplanting a composition for cell transplantation, the composition comprising a biocompatible membrane, wherein a population of Leydig-like cells derived from human pluripotent stem cells is attached to the biocompatible membrane.

[0050] G. The treatment method according to item F above, wherein the composition for cell transplantation is a sheet-shaped cell transplantation composition.

[0051] Advantageous Effects of the Invention

[0052] According to the method for preparing human pluripotent stem cell-derived Leydig-like cells of the present invention, human pluripotent stem cell-derived Leydig-like cells capable of more stably and persistently secreting testosterone can be prepared. In addition, the Leydig-like cells thus produced can be subcutaneously transplanted into mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 is a schematic diagram of the method for preparing Leydig-like cells of the present invention (Example 1).

[0054] Figure 2 The results of detecting the testosterone concentration in the culture supernatant during the preparation of Leydig-like cells are shown in comparison with the prior art method. Figure 2 A shows the comparison of culture with and without adherence. Figure 2 B shows a comparison of the addition and non-addition of the cytokine mixture (Experimental Example 1-1).

[0055] Figure 3 The results of an examination of the effects on the testosterone concentration in the culture supernatant and the duration of testosterone secretion when 8-Br-cAMP was removed from the culture medium on the 17th day after the start of culture and when 1 mM 8-Br-cAMP continued to be present after the 17th day after the start of culture in the process of preparing Leydig-like cells are shown (Experimental Example 1-2).

[0056] Figure 4The photographs show the cell morphology in the process of preparing Leydig-like cells, when 8-Br-cAMP was removed from the culture medium on the 17th day after the start of culture, and when 1 mM 8-Br-cAMP was continuously present 17 days after the end of culture, on the 55th day of culture (Experimental Example 1-2).

[0057] Figure 5 Tet-Off for forced expression of NR5A1 gene TM System and Tet-On TM Schematic diagram of the system (Experimental Examples 1-3).

[0058] Figure 6 The process of preparing Leydig-like cells using Tet-Off TM System and Tet-On TM Photographs of immunostaining images of cells in which the expression of testicular Leydig cell markers (17βHSD3, StAR, CYP17A1, and CYP11A1) was systematically examined under forced expression of the NR5A1 gene (Experimental Example 1-3).

[0059] Figure 7 The process of preparing Leydig-like cells using Tet-Off TM System and Tet-On TM Photographs of immunostaining images of cells expressing a testicular Leydig cell marker (17βHSD3) under forced expression of the NR5A1 gene (Experimental Example 1-3).

[0060] Figure 8 The testosterone concentration in the culture supernatant of the Leydig-like cells of the present invention and the cell morphology after passage are shown (Experimental Examples 1-4).

[0061] Fig. 9 The testosterone concentration in the culture supernatant of the Leydig-like cells of the present invention and the cell morphology after the second passage are shown (Experimental Examples 1-4).

[0062] Fig.10 The testosterone concentration and cell morphology of the Leydig-like cells of the present invention in the culture supernatant on day 27 after freezing and thawing are shown (Experimental Examples 1-5).

[0063] Fig.11 The testosterone concentration and cell morphology of the Leydig-like cells of the present invention during immunoisolation are shown (Experimental Examples 1-6).

[0064] Fig.12 Schematic diagram of a method for forming spheroids (cell clusters) in the method for preparing Leydig-like cells of the present invention (Example 2).

[0065] Fig.13 The testosterone concentration and cell morphology of spheroids (cell clusters) generated from the Leydig-like cells of the present invention during immunoisolation are shown (Example 2).

[0066] Fig.14 The present invention is a schematic diagram of a method for preparing a composition for cell transplantation in the method for preparing Leydig-like cells of the present invention, wherein the composition is used for transplanting Leydig-like cells into mice.

[0067] Fig.15 The cell morphology observation of culturing the Leydig-like cells of the present invention on an adherent culture dish and isolating the Leydig-like cells from the adherent culture dish and culturing the cells on a device for cell transplantation (artificial membrane of PET material) for 2 days is shown (Example 3).

[0068] Fig.16 A is a schematic diagram of a method for transplanting Leydig-like cells cultured on a device for cell transplantation into a mouse together with the device for cell transplantation. Fig.16 B shows the observation results of transplanted cells 1 week after transplantation.

[0069] Fig.17 The results of harvesting transplanted devices from mice for cell transplantation and examining the markers that are selective indicators of Leydig cells (LHCGR) by immunostaining are shown. The expression of the markers was observed at the sites where the transplanted cells were present.

[0070] Fig.18 It is a schematic diagram for explaining the method of preparing Leydig-like cells carrying the introduced Venus-Akaluc gene, which is used to examine the survival of Leydig-like cells transplanted into mice (Example 4).

[0071] Fig.19 The photographs show the morphology of the Leydig-like cells of the present invention on the 17th and 19th days after the start of culture (Example 4).

[0072] Fig. 20 A is a schematic diagram for explaining a method for preparing a cell sheet including Leydig-like cells carrying an introduced Venus-Akaluc gene and an apparatus for cell transplantation. Fig. 20 B shows Leydig-like cells on day 40 after the start of culture, before the cells were seeded on a device for cell transplantation. Fig. 20 C shows Leydig-like cells after the cells were seeded on the device for cell transplantation (Example 4) on day 41 after the start of culture.

[0073] Fig.21 A is a diagram for explaining a method for transplanting Leydig-like cells into mice. Fig.21 B shows a photograph showing the results of examining the survival of Leydig-like cells in vivo in mice using AkaBLI luminescence on day 7 after transplantation (Example 4). DETAILED DESCRIPTION

[0074] The present invention relates to a method for preparing human pluripotent stem cell-derived Leydig-like cells capable of stably and continuously secreting testosterone, prepared human pluripotent stem cell-derived Leydig-like cells, and a cell population of human pluripotent stem cell-derived Leydig-like cells. The method for preparing human pluripotent stem cell-derived Leydig-like cells of the present invention includes a step of forcibly expressing NR5A1. Human pluripotent stem cell-derived Leydig-like cells capable of more stably and continuously secreting testosterone can be prepared by the following method, the method comprising forcing human pluripotent stem cells to express NR5A1, then performing suspension culture in the presence of a cytokine mixture required for forming embryoid bodies (EBs) in a culture system, and then performing the step of adherent culture.

[0075] As used herein, the term "Leydig-like cells" refers to cells obtained by subjecting pluripotent stem cells to differentiation induction treatment, and the cells are used in a manner different from naturally occurring "Leydig cells". The "human pluripotent stem cell-derived Leydig-like cells" of the present invention refer to cells obtained by subjecting human pluripotent stem cells to differentiation induction treatment, which are capable of producing testosterone and / or expressing Leydig cell markers. For example, the Leydig cell marker is at least one marker selected from 17βHSD3, StAR, CYP17A1 and CYP11A1, and the most preferred marker is 17βHSD3. In particular, cells found to be capable of producing testosterone are also referred to as "testosterone-producing cells" as used herein.

[0076] As used herein, "pluripotent stem cells" only need to be an undifferentiated cell with "self-reproduction" and "differentiation pluripotency", the former allowing proliferation while maintaining an undifferentiated state, and the latter allowing differentiation into all three germ layer lineages. Examples include embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells). The method of the present invention includes the use of human pluripotent stem cells. Human iPS cells are very similar to human ES cells in nature, but are reported to be different from mouse ES cells in terms of transcription factor networks, epigenetics, and responses to extracellular factors (STEM CELLS 2010; 28: p.419-430; Experimental Medicine 2012; 30, No.10: p.1544-1548; and Journal of Clinical and Experimental Medicine 2011; 239, No.14: p.1247-1251). As used herein, human pluripotent stem cells are therefore considered to be different from pluripotent stem cells derived from animals other than humans.

[0077] As used herein, the term "ES cell" generally refers to a pluripotent stem cell obtained by transferring a cell aggregate (called an inner cell mass) within a blastocyst stage embryo to an in vitro culture and separating the cells into an undifferentiated stem cell population. Many human ES cell lines have been established and are available from ES Cell International Pte. Ltd., Wisconsin Alumni Research Foundation, National Stem Cell Bank (NSCB), etc.

[0078] As used herein, the term "iPS cell" refers to an induced pluripotent stem cell obtained by introducing certain kinds of genes into somatic cells and thereby inducing the reprogramming of differentiated cells, without using eggs, embryos or ES cells, and having pluripotency and proliferation potential similar to ES cells (K. Takahashi and S. Yamanaka (2006), Cell, 126: 663-676; K. Takahashi et al., (2007), Cell, 131: 861-872; J. Yu et al. (2007), Science, 318: 1917-1920; Nakagawa, M. et al., Nat. Biotechnol., 26: 101-106 (2008); and WO 2007 / 069666A1). Applicable iPS cells only need to be human iPS cells prepared by existing preparation methods or preparation methods developed in the future. The source cells used to prepare iPS cells are also not particularly limited.

[0079] The culture method or culture medium for pluripotent stem cells (such as ES cells or iPS cells) is not particularly limited and may depend on existing or future developed culture media or technologies. As a culture medium capable of maintaining the undifferentiated and pluripotent nature of ES cells, iPS cells, etc. and a culture medium suitable for differentiation induction thereof, for example, commercially available mammalian cell basal culture medium such as DMEM and / or DMEM / F12 supplemented with serum or serum replacement (KnockOut TM Serum replacement: KSR, Thermo Fisher Scientific Co., Ltd.) and bFGF, etc.; commercially available primate ES cell culture medium; basal medium hESF-GRO for primate ES cell proliferation; basal medium hESF-DIF for primate ES cell differentiation induction; and primate ES cell proliferation medium CSTI-7. Specifically, the culture medium exemplified in Patent Document 2 can be used for culture.

[0080] In the method for preparing the human pluripotent stem cell-derived Leydig-like cells of the present invention, the NR5A1 gene is introduced into the human pluripotent stem cells to form an embryoid body (EB). In order to form EB, a cytokine mixture, in particular one or more selected from the following cytokines: WNT classical pathway activator, bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF) is added to the culture system of human pluripotent stem cells. WNT classical pathway activation refers to the activation of the classical Wnt pathway, also known as the activation of the β-catenin pathway, in which the β-catenin protein regulates gene expression. The WNT classical pathway activator is specifically, for example, a glycogen synthase kinase 3 (GSK-3) inhibitor, more specifically, for example, CHIR99021. The added concentration of the WNT classical pathway activator is not particularly limited, but can be appropriately selected within the range of up to 300mM, for example, from 1mM to 300mM, from 1mM to 100mM, preferably from 10mM to 50mM, and more preferably 20mM. The concentration of BMP4 added is not particularly limited, and can be appropriately selected within the range of up to 2000 μg / mL, for example, from 10 μg / mL to 2000 μg / mL, from 10 μg / mL to 1000 μg / mL, preferably from 30 μg / mL to 500 μg / mL, and more preferably 100 μg / mL. The concentration of VEGF added is not particularly limited, but can be appropriately selected within the range of up to 2000 μg / mL, for example, from 10 μg / mL to 2000 μg / mL, from 10 μg / mL to 1000 μg / mL, preferably from 30 μg / mL to 500 μg / mL, and more preferably 100 μg / mL.

[0081] After the start of culture, human pluripotent stem cells are suitably subjected to suspension culture for 10 days or 8 days, more preferably 6 days. EBs are formed during the suspension culture process 2 to 10 days, preferably 6 to 10 days, more preferably 6 to 8 days, and most preferably 6 days after the start of culture of human pluripotent stem cells.

[0082] The culture device for suspension culture only needs to be a device capable of suspension culture and allowing EBs to be formed by three-dimensional culture, etc. In particular, a culture device capable of forming EBs of uniform size is suitable. For example, a suitable culture device is a culture device having a micropore diameter of 200 μm to 20 mm, preferably 400 μm to 1000 μm, and more preferably 400 μm or 800 μm. Specifically, AggreWell can be used. TM 400 (StemCell Technologies, Inc.), etc. Using this culture device, EBs of uniform size can be formed by inoculating cells in the form of a single cell suspension. The culture device is suitable for forming a culture device with about 50 cells to about 20,000 cells, preferably about 50 cells to about 5,000 cells, and more preferably about 100 cells to about 200 cells per EB. For example, when AggreWell TM When a 4006-well plate is used as a culture device, the plate includes 7000 cavities per well and allows one EB to form in each cavity. 6 When the number of cells increases, one EB is formed by 200 cells.

[0083] As used herein, "NR5A1 gene" can be identified by, for example, GenBank accession number NM_004959 (SEQ ID No: 1). Existing methods or any method developed in the future can be used as a method for introducing the NR5A1 gene into human pluripotent stem cells. NR5A1 cDNA can be introduced into an appropriate expression vector containing a promoter by existing methods, so that it can function in cells as a host. Specifically, the method described in Patent Document 2 can be applied.

[0084] The present invention includes a step of forcibly expressing the introduced gene in human pluripotent stem cells into which the NR5A1 gene has been introduced. The gene can be expressed by using any gene expression system currently available or developed in the future. The timing of gene expression can be adjusted by using any method currently available or developed in the future. An exemplary experimental system capable of reversibly controlling the expression of a target gene in cells, etc., is Tet-On TM / Off TM A system that provides tetracycline-dependent gene expression. This expression system allows the expression of a gene of interest to be controlled by the presence or absence of the antibiotic tetracycline or the tetracycline derivative doxycycline (Dox) added to the culture medium.TM The system takes advantage of the E. coli tetracycline resistance operator, such as the Tet repressor protein (TetR) and the Tet operator sequence (tetO sequence), and allows TetR to bind to the tetO sequence in the absence of tetracycline, resulting in forced expression of NR5A1 (see Figure 5 A and Figure 5 B).

[0085] In the method for preparing human pluripotent stem cell-derived Leydig-like cells of the present invention, Tet-Off TM System and Tet-On TM Any of these systems can be used to regulate NR5A1 gene expression. TM The system is suitable, which provides forced expression of NR5A1 in the absence of tetracycline or doxycycline. TM System, human pluripotent stem cells into which the NR5A1 gene has been introduced in advance are cultured in the presence of tetracycline or doxycycline, thereby being able to prevent their differentiation into Leydig-like cells derived from human pluripotent stem cells. Then, tetracycline or doxycycline is removed at the time when differentiation into Leydig-like cells is required, and NR5A1 can be continuously forced to be expressed. In addition, in the continuous forced expression of NR5A1, it is appropriate to remove tetracycline or doxycycline because it can avoid adverse reactions caused by these drugs. Therefore, differentiation into Leydig-like cells derived from human pluripotent stem cells can be more effectively regulated and promoted.

[0086] Tet-on / off is also described in the embodiment of Patent Document 2 (WO 2018 / 088240A1), but the description in Patent Document 2 is based on Tet-On TM The Tet-off system in the examples of Patent Document 2 is described as having no forced expression of NR5A1 in the absence of tetracycline or doxycycline, and is therefore different from the Tet-Off™ system in the present invention.

[0087] The method of preparing human pluripotent stem cell-derived Leydig-like cells of the present invention includes the step of subjecting the cells to adherent culture after suspension culture. Adherent culture refers to allowing cells to adhere to a culture container (culture device) and culture in a monolayer state. Culture dishes (laboratory culture dishes), culture flasks, multi-well plates, etc. are used as culture containers, and a culture vessel coated with, for example, Matrigel can be used. TM(manufactured by Becton, Dickinson and Company), collagen, gelatin, laminin, heparin sulfate proteoglycan, nestin or a combination thereof for adherent culture. In the adherent culture step, the human mesoderm cells can be induced to differentiate into Leydig-like cells. In the adherent culture step, it is suitable to remove the cytokine mixture (one or more cytokines present in the culture system, selected from WNT classical pathway activators, BMP4 and VEGF) added to the culture system of human pluripotent stem cells used in the suspension culture step.

[0088] In the adherent culture step, it is suitable to further treat with cAMP. When used as cAMP, 8-Br-cAMP can be added to the culture medium at a concentration of 0.01mM to 4mM, preferably 0.1mM to 1mM. In addition to treatment with cAMP, it is preferred to further stimulate with forskolin. Forskolin can be added to the culture medium at a concentration of 0.1μM to 100μM, preferably 2μM to 100μM, and more preferably 5μM to 100μM. cAMP is suitable for appropriate removal within the 8th to 40th day after the start of treatment, preferably removed 30 days after the start of culture, more preferably removed 20 days after the start of culture, and most preferably removed 17 days after the start of culture. At the same time, even after the removal of cAMP, it is preferred to add forskolin to the culture medium.

[0089] The duration of adherent culture is not particularly limited, and the culture can be continued as long as the culture can proceed. In addition, the cells can be passaged during the adherent culture step. In cell passage, it is suitable to use a cell dissociation enzyme, such as TrypLE TM Select、TrypLE TM Express or In addition, the cells can be treated with a ROCK inhibitor such as Y27632. The seeding density of cells during subculturing only needs to be a concentration that allows cell survival and is not particularly limited, for example, from 1 cell / well to 1.0×10 6 cells / well, preferably from 1000 cells / well to 1.0×10 5 cells / well, more preferably about 1.0×10 4 cells / well (9.6 cm 2 ).

[0090] In addition, cells that have undergone adherent culture can be cryopreserved. The cryopreservation method and storage conditions of cells only need to be performed by a person skilled in the art, and there is no particular limitation. Existing methods or any methods developed in the future can be applied. For example, a culture medium containing a cryoprotectant (such as dimethyl sulfoxide (DMSO) or glycerol) needs to be used as a freezing medium, or a commercially available culture medium can be used. For example, STEM-CELLBANKER can be used. TM (Zenogen Pharma), Recovery TM Cell freezing medium (Thermo Fisher Scientific Inc.) or Synth-a-Freeze TM Cryopreservation medium (Thermo Fisher Scientific Co., Ltd.) is used as a commercially available medium. During the cell freezing process, the cells can be stored at a temperature of, for example, -80°C, or in liquid nitrogen at a lower temperature. The method for thawing the frozen cells only needs to be a method performed by a person skilled in the art, and there is no particular limitation, and any existing method or any method developed in the future can be applied.

[0091] The method for preparing human pluripotent stem cell-derived Leydig-like cells of the present invention induces human pluripotent stem cells to differentiate into human pluripotent stem cell-derived Leydig-like cells with a high differentiation induction efficiency of 80% or more, preferably 90% or more, and more preferably 95% or more. The present invention also includes human pluripotent stem cell-derived Leydig-like cells and human pluripotent stem cell-derived Leydig-like cell populations prepared by the method of the present invention. The human pluripotent stem cell-derived Leydig-like cells of the present invention are capable of continuously producing testosterone for at least 60 days, preferably 120 days or more. The Leydig-like cell population of the present invention is also a human pluripotent stem cell-derived Leydig-like cell population, which contains a high ratio of 80% or more, preferably 90% or more, and more preferably 95% of Leydig-like cells capable of producing testosterone.

[0092] The human pluripotent stem cell-derived Leydig-like cells prepared by the adherent culture in the above steps can be further subjected to suspension culture. The culture device used in the suspension culture only needs to be a culture device capable of three-dimensional culture, without particular limitation, but the culture device used in the step of forming EBs from human pluripotent stem cells or the step of forcibly expressing NR5A1 in human pluripotent stem cells can be used. Specifically, for example, a culture device having a micropore diameter of 200 μm to 20 mm, preferably 400 μm to 1000 μm, and more preferably 400 or 800 μm can be used. Cultivation using such a culture device enables three-dimensional culture of human pluripotent stem cell-derived Leydig-like cells.

[0093] The present invention also includes a pharmaceutical composition containing human pluripotent stem cell-derived testicular interstitial cells or cell groups prepared by the method of the present invention as an active ingredient. The target of the pharmaceutical composition of the present invention is, for example, a disease associated with testosterone reduction or a symptom requiring testosterone replacement. The present invention also includes a therapeutic agent for a disease associated with testosterone reduction, containing human pluripotent stem cell-derived testicular interstitial cells or cell groups prepared by the method of the present invention as an active ingredient. Specific examples thereof include LOH syndrome, Klinefelter syndrome, testicular trauma, secondary hypogonadism, and cases of biologically female humans requiring androgen replacement, such as transgender people.

[0094] The pharmaceutical composition containing human pluripotent stem cell-derived Leydig-like cells or cell populations as active ingredients or therapeutic agents for diseases associated with testosterone reduction may contain, in addition to the prepared Leydig-like cells, a pharmaceutically acceptable carrier. For example, the carrier is a culture medium used in cell culture to produce Leydig-like cells. In addition, the Leydig-like cells derived from human pluripotent stem cells may be subjected to immunoisolation.

[0095] The present invention also includes a device for human pluripotent stem cell derived endocrine cell transplantation. In other words, the present invention also includes a device before the human pluripotent stem cell derived testicular interstitial-like cell group of the present invention is attached to the wall. As used herein, the term "pluripotent stem cell derived endocrine cell transplantation device" refers to a device capable of transplanting pluripotent stem cell derived endocrine cells, which allows the pluripotent stem cell derived endocrine cells to be attached to the wall when the device is used to culture, effectively secrete substances produced by pluripotent stem cell derived endocrine cells, such as hormones, particularly testosterone. The materials that can be used for pluripotent stem cell derived endocrine cell transplantation devices need to have biocompatibility, which is a characteristic that has no harmful effects on living bodies. Biocompatible materials are appropriately affinity with living bodies, and can be materials that are biologically absorbed after the human pluripotent stem cell derived interstitial-like cell group is established in the living body. Examples of such materials include synthetic polymers, such as polyethylene terephthalate (PET), poly-L-lactic acid (PLLA), polyglycolic acid (PGA), copolymers of lactic acid and glycolic acid (PLGA) and polycaprolactone (PCL). Natural polymers such as collagen, gelatin, glycosaminoglycans, chitin, chitosan, hyaluronic acid, and polypeptides can be used. The shape of the device for pluripotent stem cell-derived endocrine cell transplantation is not particularly limited, but, for example, a sheet-like device such as a biocompatible membrane can be used.

[0096] The present invention also includes a composition for cell transplantation, which includes a device for pluripotent stem cell-derived endocrine cell transplantation, and the human pluripotent stem cell-derived Leydig-like cell population of the present invention is adhered to the device. The human pluripotent stem cell-derived Leydig-like cells adhered to the device for cell transplantation can be further subjected to immunoisolation treatment. The composition for cell transplantation can be prepared by culturing the human pluripotent stem cell-derived Leydig-like cell population of the present invention on the device for cell transplantation. The shape of the composition for cell transplantation is not particularly limited as long as it allows cell transplantation, and can be, for example, sheet-like or capsule-like.

[0097] As used herein, the term "immunoisolation treatment" refers to allowing water, nutrients or hormones to pass through, but prohibiting immune cells and transplanted cells from passing through, and suppressing the rejection reaction of the cells transplanted under a local environment, without hindering the processing of angiogenesis. Any method of existing methods or future developments can be used as immunoisolation treatment. For example, immunoisolation treatment can be carried out by embedding cells in beads or capsules of, for example, alginate gel, agarose, anisotropic materials, polysulfone (PSF), nanofiber pads, polyimide, tetrafluoroethylene / polytetrafluoroethylene (PTFE), ePTFE, polyacrylonitrile, polyethersulfone, acrylic resin, cellulose acetate, cellulose nitrate, polyamide or hydroxypropylmethylcellulose (HPMC) membranes. This immunoisolation treatment can avoid some problems, such as the immune rejection reaction associated with cell transplantation, or the diffusion or invasion of cells. The immunoisolation treatment makes the human pluripotent stem cell derived testicular interstitial-like cells produced, even if not from one's own cells (not from autologous cells), it can also be used to treat the disease of the substance (particularly testosterone) produced by the testicular interstitial-like cells derived from human pluripotent stem cells that needs to be continuously supplied to an organism.

[0098] The present invention also includes a method for transplanting a human pluripotent stem cell-derived Leydig-like cell group prepared by the method of the present invention. Transplantation can be achieved by transplanting the cell group together with a pluripotent stem cell-derived endocrine cell transplantation device adhered to the cell group to a desired site in a living body, preferably subcutaneously. The transplantation target of the human pluripotent stem cell-derived Leydig-like cell group of the present invention is, for example, a disease associated with reduced testosterone or a symptom requiring testosterone replacement, such as the case of the target of the above-mentioned pharmaceutical composition. Specific examples thereof include LOH syndrome, Klinefelter syndrome, testicular trauma, secondary hypogonadism, and cases of biologically female humans who need androgen replacement, such as transgender people.

[0099] The present invention also includes a method for treating a disease associated with decreased testosterone, comprising administering a pharmaceutical composition containing a population of Leydig-like cells derived from human pluripotent stem cells as an active ingredient, a method for treating a disease associated with decreased testosterone, comprising transplanting a composition for cell transplantation, the composition for cell transplantation comprising a device for transplantation of endocrine cells derived from pluripotent stem cells, the population of Leydig-like cells derived from human pluripotent stem cells being adhered to the device, or a method for treating a symptom requiring testosterone replacement.

[0100] Example

[0101] The present invention will be described in detail with reference to the following examples for further understanding of the present invention, but it should be understood that the present invention is not limited to these examples.

[0102] (Example 1) Method for preparing Leydig-like cells

[0103] In this example, a method for preparing Leydig-like cells is described (see Figure 1 ).

[0104] 1. Spare cells

[0105] In this example, iPS cells (FFPB3AB4) were used for differentiation induction treatment.

[0106] 2. NR5A1 gene

[0107] According to the method described in Example 1 of Patent Document 2, the full-length NR5A1 gene (cDNA) identified as GenBank Accession No. NM_004959 (SEQ ID No: 1) was cloned, and an NR5A1 expression vector was constructed and transfected into iPS cells (FFPB3AB4). TM Advanced Inducible Expression System (Tet-Off TM Advanced Inducible Expression System, Clontech) forced expression.

[0108] 3. Induced differentiation into Leydig-like cells

[0109] Will pass Tet-Off TM Human iPS cells with forced expression of the NR5A1 gene (KW107_121-3-NR5A1_testis interstitial_P12+2(EX564)) were cultured at 1.4×10 6 Cells were seeded in AggreWell TMIn a 4006-well plate, the cells were cultured for 6 days using a differentiation induction medium (DMEM medium (Invitrogen) containing 15% KSR (Thermo Fisher Scientific Inc.)) containing 20 mM CHIR99021, 100 μg / mL BMP4, and 100 μg / mL VEGF as a cytokine mixture. TM Each well of a 4006-well plate has 7000 chambers, and after 6 days of culture, approximately 200 cells in one chamber form one EB.

[0110] The EB-forming KW107_121-3_NR5A1_testis interstitial_P12+2 (EX564) was placed on a plate for adherent culture (Nunc TM The cells were further cultured for 11 days in a cell culture plate (Cell-Culture Treated Multidishes) using DMEM medium (Invitrogen, containing 1 mM 8-Br-cAMP, 10 μM Y27632, 100 μM forskolin, and without KSR) containing 10% FBS, and then 8-Br-cAMP was removed on day 17. Subsequently, the cells were cultured in DMEM medium (Invitrogen) containing 10% FBS and 100 μM forskolin for adherence.

[0111] In each of the following experimental examples, KW107_121-3_NR5A1_Leydig_P12+2(EX564) or Tet-On TM Systemically treated cells (KW111_3AB4_2S6_NR5A1_Leydig) were subjected to different differentiation-inducing treatment conditions, and the properties of the resulting Leydig-like cells were examined.

[0112] (Experimental Example 1-1) Effects of Adherent Culture and Addition of Cytokine Mixture on Testosterone Secretion

[0113] In this example, the preparation method (Tet-On TM The amount of testosterone in the culture supernatant of cells prepared by a prior art method (see Example 1 of Patent Document 2) (all KW111_3AB4_2S6_NR5A1_hiPSC-derived testicular interstitial-like cells) with and without adherence culture and with and without the addition of a cytokine mixture.

[0114] 1. With or without adherent culture

[0115] Figure 2 A shows the AggreWell TMCells that were cultured in suspension and then adherently in a 4006-well plate and cells derived from a related art method as a comparative example (in a three-dimensional culture plate (PrimeSurface TM The testosterone concentration in the culture supernatant of the AggreWell (MS-9096M and MS-90240) was at the peak (from the 16th to the 26th day of culture). The testosterone concentration was determined by electrochemiluminescence immunoassay (ECLIA). The results showed that in AggreWell TM The system of starting the culture in suspension at 400 and then switching to adherent culture provided significantly higher testosterone concentrations.

[0116] 2. Add or not add cytokines

[0117] Figure 2 B shows the results of using a three-dimensional culture plate (PrimeSurface TM :MS-9096M and MS-90240) were added to the cytokine mixture on the 6th day of continuous suspension culture, and the testosterone concentration in the supernatant of the continuous suspension culture cell system without adding the cytokine mixture on the 6th day was cultured on the 28th day. The results showed that the system with the addition of the cytokine mixture had significantly higher testosterone concentration and more testosterone secretion.

[0118] (Experimental Example 1-2) Effect of Adding 8-Br-cAMP on Testosterone Secretion

[0119] In this experimental example, the role of 8-Br-cAMP in the preparation of Leydig-like cells was studied. The testosterone concentration in the culture supernatant was detected: one case in which 1 mM 8-Br-cAMP was added when the adherent culture was started on the 6th day after the start of the culture, and 8-Br-cAMP was removed from the culture medium on the 17th day after the start of the culture; and one case in which the culture medium continued to contain 1 mM 8-Br-cAMP after the 17th day after the start of the culture. The testosterone concentration was determined by the measurement method of the same technique as in Experimental Example 1.

[0120] The results showed that removing 8-Br-cAMP in the middle of the culture was more conducive to maintaining testosterone secretion ( Figure 3 The results also showed that removing 8-Br-cAMP in the middle of the culture was more conducive to the long-term survival of cells ( Figure 4 ).

[0121] (Experimental Example 1-3) Expression of Leydig Cell Markers

[0122] In this experiment, the cells were immunostained to detect the expression of Tet-Off TM System or Tet-On TMExpression of Leydig cell markers 17βHSD3, StAR, CYP17A1, and CYP11A1 in human iPS cells systematically forced to express NR5A1. TM Advanced Inducible Expression System (Clontech) or Tet-On TM The Advanced Inducible Expression System (Clontech) was used as the Tet-OffT TM System or Tet-On TM System (see Figure 5 ).

[0123] Tet-Off TM System treated cells: KW107_121-3_NR5A1_Leydig_P12+2(EX564)

[0124] Tet-On TM System treated cells: KW111_3AB4_2S6_NR5A1_Leydig

[0125] On Tet-Off TM In the system, the Leydig-like cells prepared by the method of Example 1 were passaged four times, and the cells on day 4 after the fourth passage were measured. In the Tet-On™ system, differentiation induction of iPS cells was initiated, and the cells on day 25 were measured.

[0126] The results showed that even when the NR5A1 gene was Tet-Off TM System and Tet-On TM When any of the expression vectors in the system are forced, Leydig cell markers are expressed, but when Tet-Off TM Cells that were forced to express the NR5A1 gene expressed the Leydig cell markers 17βHSD3, StAR, and CYP17A1 at higher densities. Figure 6 ). In particular, 99.9% or more of the cells were 17βHSD3 positive ( Figure 7 ). This shows that through Tet-Off TM The long-term forced expression of the NR5A1 gene in the system showed extremely high efficiency in inducing differentiation into Leydig-like cells and could obtain a higher purity Leydig-like cell population.

[0127] (Experimental Example 1-4) Testosterone secretion in cells after passage

[0128] In this experimental example, the testosterone concentration in the culture supernatant of the cells after passage was measured. The testosterone concentration was measured by the same technique as in Experimental Example 1.

[0129] Treat with cell dissociation enzyme (0.5×TrypLE Select) by the method of Example 1 (Tet-Off TM The cells cultured in the 10% FBS+100 μM forskolin-containing DMEM medium (Invitrogen) were harvested and suspended in a maintenance medium to provide a cell suspension, and then passaged from well 1 to well 5. The seeding density of the cells at this time was approximately 1×10 4 cells / well (9.6 cm 2 ). Testosterone concentrations in the culture supernatant of cells were measured on the 1st, 9th, and 15th days after passage. Testosterone secretion was 11.8 ng / mL on the 1st day after passage, 86.6 ng / mL on the 9th day, and 128 ng / mL on the 15th day ( Figure 8 ).

[0130] As in the first passage, cells that had been cultured adherently for 18 days after the first passage were treated with a cell dissociation enzyme (0.5×TrypLE Select) and suspended in a maintenance medium (10% FBS+100 μM forskolin-containing DMEM medium (Invitrogen)) to provide a cell suspension, and then passaged from well 1 to well 12. The seeding density of the cells at this time was approximately 1×10 4 cells / well (9.6 cm 2 ). Testosterone concentrations in the culture supernatant of cells were measured on days 1, 9, and 15 after passage. Testosterone secretion was 14.7 ng / mL on day 4, 71.9 ng / mL on day 11, and 139 ng / mL on day 25 after passage ( Fig. 9 ).

[0131] (Experimental Example 1-5) Testosterone secretion in cells after freezing and thawing

[0132] In this experimental example, the testosterone concentration in the culture supernatant of the cells after freezing and thawing was measured. The testosterone concentration was measured by the same technique as in Experimental Example 1.

[0133] Treat with cell dissociation enzyme (0.5×TrypLE Select) by the method of Example 1 (Tet-Off TM The cells cultured in the 48th day after the start of culture were suspended in a freezing medium (STEM-CELLBANKER), distributed into cryopreservation bottles, and cryopreserved in liquid nitrogen. The cryopreserved cells were taken out from the liquid nitrogen storage according to the conventional method, thawed, and suspended in a maintenance medium (10% FBS + 100 μM forskolin-containing DMEM medium, Invitrogen) for culture.

[0134] On day 27 after freezing and thawing, the testosterone concentration in the culture supernatant was measured. The results showed that testosterone secretion was 62.1 ng / mL ( Fig.10 ).

[0135] (Experimental Example 1-6) Testosterone secretion in Leydig-like cells treated with immunoisolation

[0136] By the method of Example 1 (Tet-Off TM The testicular interstitial cells prepared by the testicular interstitial cell culture system were passaged once, and the cells on the 18th day after passage were subjected to immunoisolation according to the following method. The testosterone concentration in the culture supernatant containing the testicular interstitial cells subjected to immunoisolation was measured. The testosterone concentration was measured by the same technique as in Experimental Example 1.

[0137] (1) Add 2 mL / well of calcium chloride solution to the Nunc TM Cell culture was plated in 12-well plates.

[0138] (2) On day 18 after subculturing, the maintenance medium of KW107_121-3_NR5A1_Leydig_P12+2 (EX564) in adherent culture was removed.

[0139] (3) Apply 400 μL / well 0.5×TrypLE select.

[0140] (4) Place the cells in a 37°C incubator containing 5% CO2 for 2 minutes.

[0141] (5) Remove the cells from the incubator and remove the 0.5×TrypLE select.

[0142] (6) Wash the cells with 1× PBS.

[0143] (7) Use 300 μL / well of sodium alginate solution.

[0144] (8) Use a pipette to suspend the cells.

[0145] (9) Use a pipette chip to pour 200 μL of the suspension in item (8) into the well in item (1).

[0146] (10) The suspension is incubated at room temperature for 5 minutes to provide Leydig-like cells embedded in the alginate beads.

[0147] (11) Remove the solution except for the beads.

[0148] (12) Add 2 mL / well of maintenance medium (10% FBS + 100 μM forskolin-containing DMEM medium).

[0149] The results showed that the immunoisolated Leydig-like cells secreted 28.3 ng / mL of testosterone ( Fig.11 ).

[0150] (Example 2) Preparation of Leydig-like cells 2

[0151] iPS cells (FFPB3AB4) were used and cultured using the same techniques as described in Sections 1 to 3 of Example 1. After removing 8-Br-cAMP on the 17th day of culture, the cells were further maintained in DMEM medium (Invitrogen) containing 10% FBS and 100 μM forskolin. The cells were treated with a cell dissociation enzyme (0.5×TrypLE Select) and harvested on the 30th day after the start of culture. The cells were washed with a culture medium by conventional methods and then suspended in a maintenance medium (DMEM medium containing 10% FBS+100 μM forskolin) to provide a cell suspension and in AggreWell TM 2.0×10 per well on a 4006-well plate 5 Cells were inoculated to form small spherical cell clusters (spheroids). TM :MS-9096M) with 1.25×10 4 cells were seeded to form large spherical cell clusters (macrospheres) ( Fig.12 ).

[0152] The macrospheres and microspheres formed within 4 days were immunoisolated by the following method, and then cultured for 3 days, and the testosterone concentration in the culture supernatant containing testicular interstitial-like cells obtained thereby was measured. The testosterone concentration was measured by the same technique as in Experimental Example 1.

[0153] (1) Add 2 mL / well of calcium chloride solution to the Nunc TM Cell culture was plated in 12-well plates.

[0154] (2) Collect each large and small sphere in the corresponding suspension culture into one test tube and remove the maintenance medium.

[0155] (3) Dispense 300 μL / well of sodium alginate solution.

[0156] (4) Use a pipette tip to pour 1000 μL of the suspension from item (3) into the separate wells of item (1).

[0157] (5) The suspension is incubated at room temperature for 5 minutes to provide Leydig-like cells embedded in the alginate beads.

[0158] (6) Remove the solution other than the spheres embedded in the beads.

[0159] (7) Add 2 mL / well of maintenance medium (DMEM medium containing 10% FBS + 100 μM forskolin) and then culture.

[0160] The results showed that Leydig-like cells isolated from large spheroids provided testosterone secretion at a concentration of 9.47 ng / mL, while Leydig-like cells isolated from small spheroids provided testosterone secretion at a concentration of 13.5 ng / mL ( Fig.13 ). The above results indicate that the formation of microspheres provides higher testosterone secretion.

[0161] (Example 3) Transplantation of Leydig-like cells

[0162] This example examines whether the Leydig-like cells of the present invention can be transplanted into mice using female mice. Using iPS cells (FFPB3AB4), and culturing using the same techniques as shown in Sections 1 to 3 of Example 1, after removing 8-Br-cAMP on the 17th day of culture, the cells were further maintained in a DMEM medium (Invitrogen) containing 10% FBS and 100 μM forskolin. On the 20th day after the start of culture, the cells were treated with a cell dissociation enzyme (0.5×TrypLE Select) and harvested. The cells were washed with a culture medium by conventional methods and then suspended in a maintenance medium (DMEM medium containing 10% FBS+100 μM forskolin) to provide a cell suspension. Preparation of Falcon TM Cell culture inserts (Falcon TM Cell Culture Inserts) are used as a device for cell transplantation, which includes an artificial membrane made of PET material, 4.5×10 5 Cells were seeded in the cell transplantation device and cultured for 2 days to provide cell sheets ( Fig.14 ). Observation of the morphology of Leydig-like cells adhered to the adherent culture dish and the device for cell transplantation ( Fig.15 ).

[0163] The cell sheet including the device for cell transplantation was subcutaneously transplanted into immunocompromised mice (24 weeks old, female) ( Fig.16 A). One week after transplantation, the device used for cell transplantation was removed from the mouse and the transplanted Leydig-like cells were observed. Angiogenesis was observed in the mouse at the site of the transplanted cell sheet, suggesting that an environment that promotes the delivery of nutrients to the transplanted Leydig-like cells may have been established ( Fig.16B) Immunostaining with an antibody against the indicated marker (LHCGR) (anti-LHR antibody) was performed to examine whether the transplanted Leydig-like cells expressed Leydig cell markers. In the area where the transplanted cells were present, the expression of the marker was observed ( Fig.17 ).

[0164] The above results show that the Leydig-like cells of the present invention can be transplanted into mice and will not fall off from the device used for cell transplantation.

[0165] (Example 4) Examination of the survival rate of transplanted Leydig-like cells

[0166] In this example, whether the Leydig-like cells of the present invention transplanted into mice survive in the mice was examined by using the artificial bioluminescence system AkaBLI (RIKEN).

[0167] iPS cells (FFPB3AB4) were used and cultured using the same techniques as described in Sections 1 to 3 of Example 1. On day 17, cells were treated with a cell dissociation enzyme (0.5×TrypLE Select), harvested, and passaged in a DMEM medium (Invitrogen) containing 10% FBS, 100 μM forskolin, and no 8-Br-cAMP. On day 2 after passage (day 19 after the start of culture), the Venus-Akaluc gene (RIKEN) was introduced using a retroviral vector ( Fig.18 ). Akaluc is an artificial enzyme that, when combined with the substrate AkaLumine, enables AkaBLI to produce light. Fig.19 Shown are Leydig-like cells on day 17 after the start of culture and cells before the introduction of the Venus-Akaluc gene (day 19 after the start of culture).

[0168] On the 21st day after the introduction of the Venus-Akaluc gene (the 40th day after the start of culture), the cells were treated with a cell dissociation enzyme (0.5×TrypLE Select) and harvested. The cells were washed with a culture medium by a conventional method and then suspended in a maintenance medium (DMEM medium containing 10% FBS+100 μM forskolin) to provide a cell suspension. The cell suspension was cultured at 1.0×10 5 The cells were seeded into a device for cell transplantation comprising an artificial membrane of PET material to produce a cell sheet ( Fig. 20 A). Fig. 20 B shows cells on day 21 after the introduction of the Venus-Akaluc gene. Fig. 20C shows cells on the second day after inoculation in the device for cell transplantation. In each case, cells not transfected with the Venus-Akaluc gene were used as controls. Cells into which the Venus-Akaluc gene was introduced expressed Venus, and even after inoculation in the device for cell transplantation, the expression of Venus could be detected on the device ( Fig. 20 B and Fig. 20 C).

[0169] The cell sheet including the device for cell transplantation was subcutaneously transplanted into immunocompromised mice (11 weeks old, female) ( Fig.21 A). On the 7th day after transplantation, AkaLumine hydrochloride was intraperitoneally injected, and then the in vivo luminescence of AkaBLI was observed using the IVIS imaging system (PerkinElmer) to detect the expression of Venus. The luminescence of AkaBLI was identified in the cell sheet of Leydig-like cells into which the Akaluc gene was introduced, proving that the transplanted Leydig-like cells survived in the living body of the mouse ( Fig.21 B).

[0170] Industrial Applicability

[0171] As described above, Leydig-like cells capable of stably and continuously secreting testosterone can be provided by a method for preparing Leydig-like cells derived from human pluripotent stem cells, the method comprising the step of culturing human pluripotent stem cells under culture conditions in which a cytokine mixture is added to force expression of NR5A1, wherein various designs are made for the time of adding or removing cAMP, suspension culture, adherent culture, etc. The Leydig-like cells derived from human pluripotent stem cells prepared by the method of the present invention are capable of stably producing testosterone for a long period of time and expressing any one of 17βHSD3, StAR, CYP17A1, and CYP11A1.

[0172] In addition, in the step of forcing NR5A1 expression, the Tet-Off TM The system continuously forces expression of NR5A1 in the absence of tetracycline, Tet-Off TMThe system uses the Tet repressor protein (TetR) and the Tet operator sequence (tetO sequence) that function in the tetracycline resistance operon of Escherichia coli, and allows TetR to bind to the tetO sequence in the absence of tetracycline. This enables the generation of Leydig-like cells at a desired time by preserving human pluripotent stem cell-derived Leydig-like cells in the presence of tetracycline, doxycycline, etc. before differentiation induction treatment, and removing tetracycline, doxycycline, etc. when differentiation induction is required. In addition, Leydig-like cells can be generated in the absence of tetracycline or doxycycline, so the adverse effects caused by these drugs can be avoided.

[0173] The Leydig-like cells prepared by the method of the present invention can be passaged and cryopreserved. In addition, the Leydig-like cells of the present invention can be transplanted to the desired part in the living body together with the composition for cell transplantation of the present invention, i.e., the device for endocrine cell transplantation derived from human pluripotent stem cells, preferably subcutaneously transplanted, and the device is, for example, a biocompatible membrane to which the Leydig-like cells of the present invention adhere. In addition, immunoisolation treatment also provides the function of testosterone-producing cells. The Leydig-like cells derived from human pluripotent stem cells of the present invention can be applied to people suffering from diseases associated with testosterone reduction or symptoms requiring testosterone replacement. Its specific examples include LOH syndrome, Klinefelter syndrome, testicular trauma, secondary hypogonadism, and cases of biologically female humans requiring male hormone replacement, such as transsexuals. The Leydig-like cells derived from human pluripotent stem cells for these situations are useful, because the cell transplantation treated with immunoisolation allows water, nutrients or hormones to pass through, but prohibits immune cells, transplanted cells, etc. from passing through, thereby preventing the rejection reaction associated with cell transplantation and the spread and invasion of cells.

Claims

1. A method for preparing Leydig-like cells derived from human pluripotent stem cells, comprising the steps of forcibly expressing NR5A1 in human pluripotent stem cells, The method comprises the step of adding one or more selected from the group consisting of: WNT classical pathway activator, bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF) to the culture system of human pluripotent stem cells.

2. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 1, wherein the method comprises forcibly expressing NR5A1 in the human pluripotent stem cells in the presence of one or more selected from WNT classical pathway activators, BMP4 and VEGF; then culturing in suspension for 2 to 10 days, followed by the step of adherent culture.

3. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 1, wherein the method comprises forcibly expressing NR5A1 in the human pluripotent stem cells in the presence of one or more selected from WNT classical pathway activators, BMP4 and VEGF; then performing suspension culture until the human pluripotent stem cells begin to form blastoderm, followed by the step of adherent culture.

4. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 2 or 3, wherein the adherent culture step comprises the step of removing the existing WNT classical pathway activator, BMP4 and VEGF, and then adding cAMP.

5. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 4, wherein the method comprises a step of removing cAMP from the culture system during the period from day 2 to day 40 after the start of treatment with cAMP.

6. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 4, wherein the adherent culture step comprises the step of removing the existing WNT canonical pathway activator, BMP4 and VEGF, and then treating with forskolin.

7. The method for preparing Leydig-like cells derived from human pluripotent stem cells according to claim 1, wherein: The step of forcibly expressing NR5A1 in human pluripotent stem cells is performed on a culture device capable of forming one embryoid body of 50 cells to 20,000 cells in the presence of one or more selected from one or more of a WNT canonical pathway activator, BMP4 and VEGF.

8. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 1, wherein the step of forcibly expressing NR5A1 in human pluripotent stem cells comprises using a Tet-Off (trademark name) system in a tetracycline-dependent gene expression system, wherein the Tet-Off system forces expression of NR5A1 in the absence of tetracycline or doxycycline.

9. The method for preparing human pluripotent stem cell-derived Leydig-like cells according to claim 2 or 3, wherein the method comprises a step of further performing suspension culture after performing suspension culture and adherent culture.

10. The method for preparing Leydig-like cells derived from human pluripotent stem cells according to claim 1, wherein: The differentiation induction efficiency from the human pluripotent stem cells to the human pluripotent stem cell-derived Leydig-like cells is 80% or more.

11. A human pluripotent stem cell-derived Leydig-like cell prepared by the method of claim 1.

12. The human pluripotent stem cell-derived Leydig-like cell according to claim 11, wherein the human pluripotent stem cell-derived Leydig-like cell is a Leydig-like cell that continuously produces testosterone for at least 60 days.

13. A human pluripotent stem cell-derived Leydig-like cell, which is obtained after the human pluripotent stem cell-derived Leydig-like cell of claim 11 is passaged at least once. 14 . A human pluripotent stem cell-derived Leydig-like cell population, comprising the human pluripotent stem cell-derived Leydig-like cells according to claim 11 . 15 . The human pluripotent stem cell-derived Leydig-like cell population according to claim 14 , wherein the human pluripotent stem cell-derived Leydig-like cell population comprises 80% or more of Leydig-like cells capable of producing testosterone. 16 . The human pluripotent stem cell-derived Leydig-like cell population according to claim 14 or 15 , wherein the human pluripotent stem cell-derived Leydig-like cell population is subjected to immunoisolation treatment.

17. A pharmaceutical composition for treating a disease associated with testosterone reduction, comprising the human pluripotent stem cell-derived Leydig-like cell population according to claim 14 or 15 as an active ingredient.

18. A composition for cell transplantation, comprising a biocompatible membrane, onto which the human pluripotent stem cell-derived Leydig-like cell population according to claim 14 or 15 is adhered.

19. A device for transplantation of endocrine cells derived from pluripotent stem cells, comprising a biocompatible membrane for implanting endocrine cells derived from pluripotent stem cells into a living body.

20. The device for pluripotent stem cell-derived endocrine cell transplantation according to claim 19, wherein the pluripotent stem cell-derived endocrine cells are human pluripotent stem cell-derived endocrine cells capable of producing testosterone.

21. The device for transplantation of endocrine cells derived from pluripotent stem cells according to claim 20, wherein: The human pluripotent stem cell-derived endocrine cell capable of producing testosterone is the human pluripotent stem cell-derived Leydig-like cell according to claim 11.